摘要
Abstract
Objective To explore the clinical effects of entecavir combined with Compound Biejia Ruangan Tablet (复方鳖甲软肝片) in the treatment of chronic hepatitis B with hepatic fibrosis. Methods A total of 100 patients with chronic hepatitis B liver fibrosis were randomly divided into the control group and the observation group, with 50 cases in each group. The control group was given oral administration of entecavir tablets, and the observation group, on the basis of the control group, was given Compound Biejia Ruangan Tablet (复方鳖甲软肝片) treatment. The Th17 cell surface CXC chemokine receptor 3 (CXCR3) and CC chemokine receptor 6 (CCR6) and CC chemokine receptor 4 (CCR4) expression level and the thickness of spleen, portal vein diameter, human procollagen type Ⅲ (PC-Ⅲ), collagen Ⅳ (Ⅳ-C), laminin (LN), hyaluronic acid (HA), alanine aminotransferase (ALT), total bilirubin Hormone (TBil), hepatitis B virus deoxyribonucleic acid (HBV-DNA) level of two groups before and after treatment were observed. Results After treatment, the CXCR3, CCR6, TBil, ALT and CCR4 expression percentage in the observation group were significantly lower than the control group (P＜0.05); after treatment, the serum levels of PC-Ⅲ, LN, Ⅳ-C and HA were significantly lower than control group (P＜0.05); after treatment, the spleen thickness, diameter of portal vein in the observation group were significantly lower than the control group (P＜0.05); after treatment, there were no statistically significant differences in the levels of HBV-DNA in the two groups after treatment (P＞0.05). Conclusion Compound Biejia Ruangan Tablet (复方鳖甲软肝片) combined with entecavir in the treatment of chronic hepatitis B liver fibrosis can significantly reduce the degree of liver fibrosis, improve liver function, down-regulate the percentage of CXCR3, CCR6, CCR4 expression.关键词
慢性乙型病毒性肝炎/肝纤维化/恩替卡韦/复方鳖甲软肝片/临床疗效Key words
Chronic viral hepatitis B/Hepatic fibrosis/Entecavir/Compound Biejia Ruangan Tablet (复方鳖甲软肝片)/Clinical efficacy分类
医药卫生
